Drug Repurposing Research Shows Promise for Alzheimer's

A comprehensive review published in Ageing Research Reviews reveals promising new directions for Alzheimer's disease treatment through drug repurposing strategies. With over 55 million people worldwide living with dementia and projections reaching 139 million by 2050, researchers are exploring how existing medications with established safety profiles could be reimagined for neurodegenerative care.

What This Study Found

The research team, led by More PS and colleagues, conducted an extensive analysis of drug repurposing opportunities for Alzheimer's disease (AD). The study suggests that traditional approaches focusing solely on amyloid plaques and tau proteins may be insufficient given the complex, multifactorial nature of the disease.

Researchers found that several classes of existing medications show potential for AD treatment:

Antidiabetic medications emerged as particularly promising candidates. The study highlights metformin and GLP-1 receptor agonists as potential therapeutic options, suggesting these drugs may address multiple pathological pathways involved in neurodegeneration.

Anti-hypertensive agents like candesartan were identified as having neuroprotective properties that could benefit AD patients, indicating cardiovascular health and brain health may be more interconnected than previously understood.

Anti-inflammatory drugs including NSAIDs and pioglitazone showed potential for addressing the neuroinflammation component of Alzheimer's pathology, which researchers suggest plays a crucial role in disease progression.

Perhaps most significantly, the study found that mitochondrial dysfunction represents an early and essential factor in AD development. Researchers identified several mitochondria-targeted therapeutics, including SS-31, Mdivi-1, MitoQ, DDQ, and SkQ1, as promising disease-modifying options that could address this fundamental cellular dysfunction.

Clinical Significance

This research suggests a paradigm shift in Alzheimer's treatment approaches may be necessary. Current FDA-approved therapies, including cholinesterase inhibitors and NMDA receptor antagonists, primarily provide symptomatic relief without addressing underlying disease mechanisms. Even recently approved anti-amyloid monoclonal antibodies have shown limited clinical efficacy while presenting safety and cost concerns.

The study's findings suggest that drug repurposing could offer several advantages over traditional drug development. Since these medications already have established safety profiles and known pharmacokinetic properties, researchers indicate they could potentially reach patients faster than novel compounds requiring extensive clinical testing.

The multi-target approach highlighted in the research is particularly significant. Rather than focusing on single pathways, the study suggests that addressing multiple aspects of AD pathology simultaneously—including amyloid aggregation, tau pathology, neuroinflammation, synaptic dysfunction, and mitochondrial health—may prove more effective than current single-target strategies.

Researchers also noted the potential for artificial intelligence, multi-omics approaches, and precision medicine to enhance drug repurposing efforts, suggesting these technologies could help identify optimal treatment combinations for individual patients.

Current Access and Compliance Context

Many of the medications identified in this research are already available for their original indications, which could facilitate off-label research and eventual clinical applications. Metformin, for instance, is widely prescribed for type 2 diabetes, while various anti-hypertensive and anti-inflammatory medications are commonly used in clinical practice.

However, it's important to note that using these medications for Alzheimer's treatment would require careful medical supervision and likely represent off-label use until specific approvals are obtained. The study emphasizes that while drug repurposing offers advantages in terms of known safety profiles, rigorous clinical testing would still be necessary to establish efficacy for AD treatment.

The researchers suggest that regulatory pathways for repurposed drugs may be more streamlined than those for entirely new compounds, potentially accelerating access to effective treatments for patients facing this devastating condition.

What Patients Should Know

While this research offers hope for new treatment approaches, patients and families should understand that these findings represent early-stage research and potential future directions rather than immediately available treatments. The study's authors emphasize that current evidence comes from various preclinical and observational studies, and controlled clinical trials would be necessary to confirm efficacy and safety for AD treatment.

Patients currently taking any of the medications mentioned in the study for other conditions should not modify their treatment regimens without consulting their healthcare providers. The dosing, timing, and monitoring requirements for potential AD treatment may differ significantly from those used for the drugs' original indications.

The research suggests that personalized medicine approaches may become increasingly important in AD treatment. This could mean that different patients might benefit from different combinations of repurposed medications based on their individual disease characteristics and genetic profiles.

Families dealing with Alzheimer's disease should maintain realistic expectations while remaining hopeful about these research directions. The study indicates that effective AD treatment will likely require combination approaches targeting multiple disease pathways rather than single "silver bullet" solutions.

For patients interested in clinical trials involving drug repurposing for Alzheimer's disease, consulting with specialists familiar with current research opportunities may provide access to cutting-edge treatment approaches while contributing to scientific knowledge.

If you're seeking specialized care for neurodegenerative conditions or interested in emerging treatment approaches, consider consulting with healthcare providers who stay current with the latest research developments. Visit peptideassociation.org/find-a-doctor to connect with qualified professionals in your area.

Medical Disclaimer: This content is for educational purposes only and should not be considered medical advice. Always consult with qualified healthcare providers for personalized medical guidance and treatment decisions.

Citation: More PS, Rangari SW, Lade SN, et al. Drug repurposing in Alzheimer's disease: Emerging therapeutic strategies and promising candidates. Ageing Res Rev. 2026;103113. doi:10.1016/j.arr.2026.103113